Foundation Medicine, Ophthotech Enjoy First-Day IPO Pops
This article was originally published in The Pink Sheet Daily
Executive Summary
The flood of new listings continued unabated, as a trio of offerings followed three successful IPOs last week. Cancer diagnostics start-up Foundation Medicine and “wet” AMD therapy developer Ophthotech outperformed expectations, pricing above their ranges and selling more shares than anticipated.
You may also be interested in...
Device/Diagnostics Quarterly Deal Statistics, Q3 2013
Device and diagnostics companies both suffered declines in fundraising compared with previous quarters. The biggest medtech acquisition was Stryker’s $1.4 billion buyout of MAKO, while in diagnostics BioMeriux’s $450 million purchase of BioFire topped the list.
Eyeing Epilepsy Franchise, SAGE Therapeutics Raises $20M
ARCH Venture Partners joined original investor Third Rock Ventures in backing the Cambridge, Mass., start-up with $20 million in Series B money. SAGE is concentrating its efforts on several compounds, including one to treat a type of epileptic seizure, which could represent the beginning of a larger epilepsy franchise.
Biotech IPOs Are Back: First Four For Fall Hit The Road
After a slow August and early September, Wall Street is preparing for four biotech IPOs. Biotech IPOs have been on fire, outperforming even the vigorous biotech indices. But the question remains – can public investors get too much of a good thing?